Clodronic acid in the treatment of postmenopausal osteoporosis

Tanakol R., Yarman S., Bayraktaroglu T., Boztepe H., Alagol F.

CLINICAL DRUG INVESTIGATION, vol.27, no.6, pp.419-433, 2007 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 27 Issue: 6
  • Publication Date: 2007
  • Doi Number: 10.2165/00044011-200727060-00005
  • Journal Name: CLINICAL DRUG INVESTIGATION
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.419-433
  • Istanbul University Affiliated: Yes

Abstract

Background: Clodronic acid, a first-generation bisphosphonate, has been successfully used in the treatment of high bone turnover states, Paget's disease and osteolytic bone metastases. However, controversies remain over its optimal dosage and method of administration in the treatment of postmenopausal osteoporosis. In this study we aimed to evaluate the effect of clodronic acid treatment for 3 years on bone mineral density (BMD) in women with postmenopausal osteoporosis.